

Newborn use only

| Alert | High risk medicine. Phenobarbital is reported in mg/L. To convert to micromol/L, multiply by 4.306. | | | | | | | | | | | | | | |
|------------------------------|--|--|--|------------|--------------|--|------------------------------|----------------------|--|----------|---|------------------------------------|-----------------------|---|---|
| Indication | <ol style="list-style-type: none"> 1. Treatment of neonatal seizures. 2. Initial treatment of non-opioid neonatal abstinence syndrome (NAS). 3. Add-on treatment of opioid NAS uncontrolled by morphine at maximum dose (if 3 consecutive NAS scores average ≥ 8 or 2 consecutive NAS scores average ≥ 12). 4. Treatment of hyperbilirubinaemia (unclear role). 5. Treatment of cholestasis (unclear role). 6. Preparation for liver scintigraphy (unclear role). | | | | | | | | | | | | | | |
| Action | Enhances inhibitory neurotransmission via activation of GABA receptor. | | | | | | | | | | | | | | |
| Drug type | Anticonvulsant. Sedative. | | | | | | | | | | | | | | |
| Trade name | Fawns & McAllan Phenobarbitone Sodium Solution for injection; Phenobarbitone (Aspen) Solution for injection; Phenobarbitone Aspen Tablets; Phenobarbitone Elixir | | | | | | | | | | | | | | |
| Presentation | IV: 200 mg/mL ampoule (contains 10% alcohol and 67.8% propylene glycol) Oral: 15 mg/5 mL oral liquid (contains 9.6% alcohol); 10 mg/mL and 9mg/mL alcohol free liquid can be manufactured by local pharmacy; 30 mg tablets. | | | | | | | | | | | | | | |
| Dose | <p>Anticonvulsant</p> <p>IV Loading dose 20 mg/kg/dose infusing with a maximum infusion rate of 1 mg/kg/minute.</p> <p>Additional IV loading doses 10 mg/kg may be administered at 30 minute intervals if necessary with a maximum cumulative loading dose of 40 mg/kg.</p> <p>IV or Oral Maintenance dose: 4 mg/kg/dose DAILY (3–5 mg/kg/dose), to commence 24 hours after the loading dose. Titrate the dose as per seizure control and therapeutic concentrations.</p> <p>Other indications</p> <table border="1"> <thead> <tr> <th>Indication</th> <th>Loading dose</th> <th>Maintenance dose 24 hours after loading dose</th> </tr> </thead> <tbody> <tr> <td>Neonatal Abstinence Syndrome</td> <td>15 mg/kg ORAL</td> <td>5 mg/kg/day in 1–2 divided doses ORAL and titrate to NAS score.</td> </tr> <tr> <td>Jaundice</td> <td>-</td> <td>5 mg/kg every 24 hours ORAL</td> </tr> <tr> <td>Liver scintigraphy(7)</td> <td>-</td> <td>5 mg/kg/day in 2 divided doses ORAL for 5 days prior to scan</td> </tr> </tbody> </table> | | | Indication | Loading dose | Maintenance dose 24 hours after loading dose | Neonatal Abstinence Syndrome | 15 mg/kg ORAL | 5 mg/kg/day in 1–2 divided doses ORAL and titrate to NAS score. | Jaundice | - | 5 mg/kg every 24 hours ORAL | Liver scintigraphy(7) | - | 5 mg/kg/day in 2 divided doses ORAL for 5 days prior to scan |
| Indication | Loading dose | Maintenance dose 24 hours after loading dose | | | | | | | | | | | | | |
| Neonatal Abstinence Syndrome | 15 mg/kg ORAL | 5 mg/kg/day in 1–2 divided doses ORAL and titrate to NAS score. | | | | | | | | | | | | | |
| Jaundice | - | 5 mg/kg every 24 hours ORAL | | | | | | | | | | | | | |
| Liver scintigraphy(7) | - | 5 mg/kg/day in 2 divided doses ORAL for 5 days prior to scan | | | | | | | | | | | | | |
| Dose adjustment | Therapeutic hypothermia – No dose adjustment (19) | | | | | | | | | | | | | | |
| Maximum dose | | | | | | | | | | | | | | | |
| Total cumulative dose | | | | | | | | | | | | | | | |
| Route | IV and oral | | | | | | | | | | | | | | |
| Preparation | <p>IV: Draw up 1 mL (200 mg of Phenobarbital) and add 9 mL water for injection to make final volume of 10 mL with a final concentration of 20 mg/mL.</p> <p>Oral elixir or liquid: Draw up prescribed dose.</p> <p>Oral tablet: Pregnant staff are not to crush or disperse tablets. Crush and dissolve a 30 mg tablet in 3.75 ml of water for injection to make a final concentration of 8 mg/mL solution. Give prescribed amount, discard unused portion.</p> | | | | | | | | | | | | | | |
| Administration | <p>IV:</p> <p>Loading dose: Infuse over 20 minutes with a maximum infusion rate 1 mg/kg/minute using a light safe extension set.</p> <p>Maintenance dose: Bolus over 5 minutes.</p> <p>Oral:</p> <p>Give immediately before or with feeds to minimise GI irritation.</p> | | | | | | | | | | | | | | |
| Monitoring | <p>Serum concentrations for seizure control and therapeutic hypothermia: 24 hours after starting phenobarbital. Serum target: 15–40 mg/L (65-172 micromol/L). Consider repeating concentrations 1 week after the commencement and subsequent concentrations as per clinical need.</p> <p>Consider liver function tests.</p> | | | | | | | | | | | | | | |
| Contraindications | Hypersensitivity to phenobarbital or any ingredients. Any forms of acute porphyria. | | | | | | | | | | | | | | |
| Precautions | Use with caution in renal or hepatic impairment. | | | | | | | | | | | | | | |

| | |
|--------------------------|--|
| | Dependence may develop with prolonged use – consider weaning instead of abrupt withdrawal (Refer to special comments section). Therapeutic hypothermia may increase the serum concentrations of phenobarbital |
| Drug interactions | Morphine, fentanyl, midazolam and other CNS depressants may have an additive effect with phenobarbital in causing respiratory depression. Consider starting phenobarbital at the lower end of the dose range in these patients. Blood concentrations of digoxin, metronidazole, corticosteroids (e.g. betamethasone, dexamethasone), vitamin D, and beta-blockers (e.g. propranolol, sotalol) may be reduced if administered concurrently with phenobarbital. Concurrent administration of phenytoin with phenobarbital has variable effects on serum concentrations of either drug. Serum concentrations should be monitored for both drugs. |
| Adverse reactions | Drowsiness, lethargy - sucking reflex may be impaired and feeding may be poor. Respiratory depression, apnoea. Hypotension, laryngospasm, bronchospasm, apnoea - if IV administration is too rapid. Phlebitis, tissue necrosis if extravasation occurs. GI intolerance. Physical dependence and tolerance. May occur with prolonged use: Folate deficiency, hepatitis, hypocalcaemia. |
| Compatibility | Fluids (16,17): Sodium chloride 0.45%, sodium chloride 0.9%, glucose 5%, glucose 10%. Y-site (16,17): Amino acid solutions, aciclovir, amikacin, aminophylline, amphotericin B lipid complex, amphotericin B liposome, atenolol, atropine, azathioprine, azithromycin, aztreonam, calcium chloride, calcium gluconate, cefazolin, ceftazidime, ceftriaxone, chloramphenicol sodium succinate, chlorothiazide, clindamycin, cloxacillin, dactinomycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, dopamine, enalaprilat, epoietin alfa, fentanyl, fluconazole, fluorouracil, folic acid (sodium salt), furosemide, ganciclovir, gentamicin, heparin sodium, hydrocortisone sodium succinate, ibuprofen lysine, indomethacin, insulin regular, labetalol, linezolid, lorazepam, magnesium sulfate, meropenem, methylprednisolone sodium succinate, metronidazole, milrinone, morphine sulfate, naloxone, nitroglycerin, nitroprusside sodium, octreotide, oxacillin, pamidronate, pancuronium, pentobarbital, pentoxifylline, piperacillin, piperacillin/tazobactam, potassium acetate, potassium chloride, propofol, propranolol, ranitidine, rocuronium, sodium acetate, sodium bicarbonate, theophylline, tobramycin, tolazoline, urokinase, vancomycin, vasopressin, vecuronium, voriconazole. Variable compatibility: ampicillin, benzylpenicillin, erythromycin lactobionate, hydralazine, imipenem-cilastatin, lidocaine, pantoprazole, penicillin G potassium, penicillin G sodium, succinylcholine. |
| Incompatibility | Fluids: Lipid emulsions. Y-site (16,17): Adrenaline, amiodarone, amphotericin B cholesteryl sulfate complex, atracurium, caspofungin, cefotaxime, ceftiofur, cefuroxime, diazepam, diltiazem, dobutamine, epinephrine, midazolam, norepinephrine, papaverine, phenytoin, protamine, pyrodoxine, sulfamethoxazole-trimethoprim, suxamethonium, thiamine, verapamil. |
| Stability | Use diluted/opened solution as soon as possible. |
| Storage | Protect from light. Store below 25°C. Schedule 4 Appendix D (S4D) medication. |
| Excipients | |
| Special comments | Elimination half-life: In infants 28-41 weeks gestation: Half-life of the drug was estimated (mean±SD) to be 114-2 ± 43.0 h, 73.19 ± 24.17 h and 41.23 ± 13.95 h in patients 1 - 10, 11 - 30 and 31 - 70 days old, respectively; neonates with perinatal asphyxia undergoing hypothermia 173.9±62.5 hours. Converting from mass units to SI units: 1 mg/L = 4.306 micromol/L. The general taper recommended for phenobarbital is 10-25% of the original dose every month. A faster taper is recommended for patients on therapy for less than 1 month ¹⁸ |
| Evidence | Efficacy: Treatment of neonatal seizures: Phenobarbital has been recommended as first-line treatment for neonatal seizures.[1] In RCTs, phenobarbital (target plasma concentration 25 mg/L) was reported to be similarly as effective as phenytoin (target plasma concentration 3 mg/L) for control of electrical seizures (43% versus 45%)[2]; and phenobarbital 20 mg/kg was reported to be more effective than phenytoin 20 mg/kg at controlling clinical seizures (72% versus 15%)[3] (LOE II, GOR C). Prevention of seizures in infants with perinatal asphyxia: In term or near-term infants with perinatal asphyxia, prophylactic phenobarbital (20–40 mg/kg loading dose) prevents seizures. There was no reduction in mortality and there are few data addressing long-term outcomes (LOE I, GOR C). |

| | |
|------------------------|---|
| | <p>Treatment of neonatal abstinence syndrome (NAS): Phenobarbital is recommended as add on treatment of NAS secondary to opioid withdrawal not controlled by an opioid (LOE I, GOR C).[4] Phenobarbital is recommended as initial treatment of NAS secondary to sedative withdrawal (LOE I, GOR C).[4] Phenobarbital should be commenced at a dose of 5 mg/kg/day split into two divided doses. The dose should be titrated to achieve control of NAS according to the NAS score. It is unclear whether a loading dose of phenobarbital should be used. If used as initial therapy (rather than in addition to an opioid), then a loading dose is likely to achieve more rapid control of symptoms.[5, 6]</p> <p>Treatment of hyperbilirubinaemia: A meta-analysis (3 RCTs, 497 infants) found phenobarbital (loading dose 10–30 mg/kg; maintenance 5 mg/kg/day) reduced peak serum bilirubin, duration of and need for phototherapy and need for exchange transfusion in preterm very low birth weight neonates. There are not enough data to evaluate adverse effects and neurodevelopmental outcome (LOE I, GOR C).</p> <p>Preparation for hepatobiliary scintigraphy and treatment of neonatal cholestasis: The role of phenobarbital in preparation for hepatobiliary scintigraphy is unclear. [7] (LOE I, GOR C). Phenobarbital may have a role in treatment of pruritis caused by intrahepatic cholestasis.[8]</p> <p>Pharmacokinetics and pharmacodynamics: In infants with seizures, phenobarbital 15–20 mg/kg loading dose with additional 5–10 mg/kg doses to maximal plasma concentration of 40 mg/L (172 micromol/L) resulted in a plateau of the response rate. Plasma concentrations >50 mg/L (215 micromol/L) were associated with sedation and feeding difficulty.[9]</p> <p>The clearance of phenobarbital increases with birth weight and postnatal age, but is reduced at a concentration >50 mg/L (215 micromol/L). [10] Bioavailability is 50% after oral administration. Simulations recommend a loading dose 20 mg/kg and maintenance 2.5 – 5 mg/kg/day for intravenous administration and; loading dose 40 mg/kg and maintenance 5 – 11 mg/kg/day for oral administration to meet a target phenobarbital concentration between 15 and 30 mg/L (64.5 and 129.1 micromol/L) [11]. (LOE IV GOR C)</p> <p>The clearance may also be reduced in infants with perinatal asphyxia undergoing therapeutic hypothermia.[12-14] In term infants treated with hypothermia, an initial phenobarbital loading dose of 20 mg/kg with an additional 10–20 mg/kg if needed is recommended. [14] (LOE IV GOR C)</p> |
| Practice points | |
| References | <ol style="list-style-type: none"> 1. Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. <i>Journal of child neurology</i>. 2013;28:351-64. 2. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, Paneth N, Minnigh B, Alvin J. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. <i>The New England journal of medicine</i>. 1999;341:485-9. 3. Pathak G, Upadhyay A, Pathak U, Chawla D, Goel SP. Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. <i>Indian pediatrics</i>. 2013;50:753-7. 4. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. <i>Cochrane database of systematic reviews</i>. 2010:CD002053. 5. National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn. Ministerial Council on Drug Strategy; 2006. 6. Guidelines for the management of substance use during pregnancy birth and the postnatal period. NSW Ministry of Health; 2014. 7. Malik D, Khan SH, Ali SW, Rather TA, Pakala R, Hassan MU, Yadav N, Pasupula M. Comparison of phenobarbitone and ursodeoxycholic acid in drug-augmented hepatobiliary scintigraphy for excluding the diagnosis of obstructive cholestasis in neonatal cholestasis syndrome. <i>Nuclear medicine communications</i>. 2015;36:827-32. 8. Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. <i>Am J Health-Syst Pharm</i>. 2007;64:1157-62. 9. Gilman JT, Gal P, Duchowny MS, Weaver RL, Ransom JL. Rapid sequential phenobarbital treatment of neonatal seizures. <i>Pediatrics</i>. 1989;83:674-8. 10. Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M. Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. <i>J Clin Pharm Ther</i>. 2011;36:704-10. |

| | |
|--|--|
| | <p>11. Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. <i>Fundam Clin Pharmacol.</i> 2014;28:465-71.</p> <p>12. Filippi L, la Marca G, Cavallaro G, Fiorini P, Favelli F, Malvagia S, Donzelli G, Guerrini R. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. <i>Epilepsia.</i> 2011;52:794-801.</p> <p>13. Shellhaas RA, Ng CM, Dillon CH, Barks JD, Bhatt-Mehta V. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. <i>Pediatr Crit Care Med.</i> 2013;14:194-202.</p> <p>14. van den Broek MP, Groenendaal F, Toet MC, van Straaten HL, van Hasselt JG, Huitema AD, de Vries LS, Egberts AC, Rademaker CM. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. <i>Clin Pharmacokinet.</i> 2012;51:671-9.</p> <p>15. Alonso Gonzalez AC, Ortega Valin L, Santos Buelga D, Garcia Sanchez MJ, Santos Borbujo J, Monzon Corral L, Dominguez-Gil Hurlle A. Dosage programming of phenobarbital in neonatal seizures. <i>J Clin Pharm Ther</i> 1993;18(4):267-70.</p> <p>16. Micromedex. Phenobarbital sodium injection. Accessed on 4 April 2021.</p> <p>17. Australian Injectable Drugs Handbook, 8th Edition. Accessed on 4 April 2021.</p> <p>18. St. Louis EK, Gidal BE, Henry TR, Kaydanova Y, Krumholz A, McCabe PH, et al. Conversions between monotherapies in epilepsy: Expert consensus. <i>Epilepsy and Behaviour</i> 2007;11:222-234.</p> <p>19. Lutz IC, Allegaert K, de Hoon JN, Marynissen H. Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review. <i>BMJ paediatrics open.</i> 2020;4(1).</p> |
|--|--|

| VERSION/NUMBER | DATE |
|----------------------------|------------|
| Original 1.0 | 21/06/2016 |
| Version 1.1 | 16/11/2020 |
| Current 2.0 | 04/04/2021 |
| Current 2.0 (minor errata) | 18/07/2024 |
| REVIEW | 04/04/2026 |

Authors Contribution

| | |
|--|---|
| Original author/s | Srinivas Bolisetty, David Osborn |
| Evidence Review | David Osborn |
| Expert review | Kavitha Kothur, Deepak Gill, John Lawson, Annie Bye |
| Nursing Review | Eszter Jozsa, Kirsty Minter |
| Pharmacy Review | Jing Xiao, Mariella De Rosa, Ushma Trivedi, Thao Tran, Wendy Huynh, Michelle Jenkins, Carmen Burman, Helen Huynh, Jessica Mehegan, Sarah Woodland |
| ANMF Group contributors | Chris Wake, Nilkant Phad, Himanshu Popat, Bhavesh Mehta, John Sinn |
| Final editing and review of the original | Ian Whyte |
| Electronic version | Cindy Chen, Ian Callander |
| Facilitator | Srinivas Bolisetty |